About: Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by Juliette Lambert et al published January 2019 in Haematologica

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в січні 2019 (uk) article scientifique publié en 2019 (fr) im Jahr 2019 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by Juliette Lambert et al published January 2019 in Haematologica (en)
publication date	wds:Q60922701-A5B47A6A-3D28-4324-AFED-DE82D15D56A6
publication date	2019-01-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q60922701-05BFD6CF-51E1-4495-8E8F-2700437FF6CC
language of work or name	English
cites work	wds:Q60922701-2264EEF3-FA6F-4A00-9B4F-B5E338B181B6 wds:Q60922701-326C16EF-4B52-40C1-B557-D686AFC0A55A wds:Q60922701-49369AE7-1C54-4738-804C-BDD8EAAC3CB0 wds:Q60922701-88626244-C21C-474C-A455-255CC8DFD0AD wds:Q60922701-A74976CD-5EEA-4ECB-A5D0-5D88D0162AAA wds:Q60922701-B94B9CFD-7A98-45E5-B33D-C9FE41DDA3EB wds:Q60922701-DF910702-2D15-4135-9718-9C5A5941F6D1 wds:Q60922701-F165040A-A02D-4ADC-99DB-8B09D47C24E9 wds:Q60922701-F37442CF-4AC0-45AE-A5CF-A5BE7769A447
cites work	The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
author name string	wds:Q60922701-19406D63-9E5D-4520-97AA-AA1969306E28 wds:Q60922701-24041CF9-245F-435B-8FBF-24EE719824BD wds:Q60922701-3B2EAA7E-EDDB-4B28-B6F5-84A874B79793 wds:Q60922701-3BD9695B-83C3-4123-B330-3AFFD95C00AF wds:Q60922701-3DCE7248-F53E-445C-BC5B-E24E58B5BB3C wds:Q60922701-6B0C3368-FA79-41A6-B9F1-C394F99C25E0 wds:Q60922701-7A7D424F-7344-4532-9E74-41E66B9E9D17 wds:Q60922701-7ACAA196-4440-454E-A00B-BA2868000D4E wds:Q60922701-8CCF5A5B-F703-41A4-8BD6-922DA5EB34F6 wds:Q60922701-ADA126A5-DA32-4C6E-A9E7-406B0729FC83 wds:Q60922701-CE8DAF04-F5CC-46BE-9227-5A45A0532CC9 wds:Q60922701-E133F401-7B25-4F7E-AE13-707F620C2966 wds:Q60922701-EBB6FD15-EE4B-42B2-BCFE-DC88FED3159F wds:Q60922701-F1147090-0547-41B5-95B8-1EE1F48EF198 wds:Q60922701-FED28725-07EF-4764-BC06-4FFD45EF458E
author name string	Sylvie Chevret Xavier Thomas Stephen D Rubin Emmanuel Raffoux Ollivier Legrand Pascal Turlure Christine Terré Denis Caillot Cécile Pautas Sylvie Castaigne Claude Gardin Juliette Lambert Rebecca J Benner Karïn Gogat-Marchant Pierre Bousset
rdfs:label	Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial (en) Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial (nl)
skos:prefLabel	Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial (en) Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial (nl)
name	Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial (en) Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial (nl)
author	wds:Q60922701-BE193F29-4132-411E-8288-45F0D2DCE869 wds:Q60922701-D4E67808-EAAA-434D-8396-F1F3B80938FF
author	Hervé Dombret Claude Preudhomme
title	wds:Q60922701-F84FEBA8-3422-4865-92FD-74339E3D90ED
title	Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial (en)
page(s)	wds:Q60922701-C7F13A6C-4F1E-43D1-923C-4B96C89CE563
page(s)	113-119
instance of	wds:Q60922701-22264FD5-E75A-41BB-AAC2-88B8DFBC05C6
instance of	scholarly article
main subject	wds:Q60922701-5A805671-707A-47BE-AFD7-7A2020F0898E wds:Q60922701-7C15515C-6898-45D7-A302-6EEF819AB763 wds:Q60922701-E52E4B7D-7F1D-4148-809E-6A5CF808BACE wds:Q60922701-F2FA9695-F8E0-4491-A12D-633C7321F82B
main subject	leukemia hematology acute myeloid leukemia phase III clinical trial
PubMed ID	wds:Q60922701-30714F9F-344F-4EA0-9899-914C730EAC2E
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30076173
PubMed ID	30076173
published in	wds:Q60922701-E3DE3CF5-FCC0-4DFC-A56F-BAF162B1DA7F
published in	Haematologica
issue	wds:Q60922701-A9C33662-8AE8-44EB-B0CC-449ACECFEFA6
volume	wds:Q60922701-F4DF58BF-D882-4CA4-B795-2A73250C3DFF
issue	1
volume	104
DOI	wds:Q60922701-9B0185BE-21DD-49E3-846D-891BE56D8FD7
DOI	http://dx.doi.org/10.3324/HAEMATOL.2018.188888
DOI	10.3324/HAEMATOL.2018.188888
PMCID	wds:Q60922701-0B808B8E-B835-4851-A129-C68485942294
PMCID	6312010
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q60922701
is cites work of	Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment Post-remission Therapy with Repeated Courses of High Dose Cytarabine, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favorable and Intermediate-Risk AML

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software